A literature review on the parvovirus B19 infection in sickle cell anemia and β-thalassemia patients

被引:11
|
作者
Soltani, Saber [1 ]
Zakeri, Armin [2 ]
Tabibzadeh, Alireza [3 ]
Zandi, Milad [1 ]
Ershadi, Elham [1 ]
Rezayat, Sara Akhavan [4 ]
Khaseb, Sanaz [2 ]
Zakeri, Amir Mohammad [5 ]
Nakhaei, Mohammadvala Ashtar [6 ]
Afzali, Shervin [6 ]
Farahani, Abbas [7 ]
机构
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran
[2] Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran, Iran
[3] Iran Univ Med Sci, Dept Virol, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Care Management & Econ, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Pediat Surg Res Ctr, Res Inst Childrens Hlth, Tehran, Iran
[6] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Dept Cellular & Mol Biol, GC, Tehran, Iran
[7] Hormozgan Univ Med Sci, Infect & Trop Dis Res Ctr, Hormozgan Hlth Inst, Bandar Abbas, Iran
关键词
Parvovirus B19; Sickle cell anemia; β -thalassemia;
D O I
10.1186/s41182-020-00284-x
中图分类号
R188.11 [热带医学];
学科分类号
摘要
Background Parvovirus B19 is the causative agent for erythema infectiosum, and also as a potentially life-threatening infectious agent, it is mainly presented in high erythrocyte turnover patients. Sickle cell disease (SCD) is an inherited monogenic hematological disorder resulting from the mutations in the hemoglobin beta-chain gene. Thalassemia is a hereditary hematological syndrome that happens in consequence of deficiencies in the production of one or more globin chains. We summarize current knowledge about the prevalence rates of the parvovirus B19 infection in sickle cell anemia and thalassemia patients. Methods Several online databases were searched including, Scopus, EMBASE, Web of Science, Google Scholar, and PubMed, which were performed amidst 2009-2019 by using distinct keywords: "Thalassemia," "Parvovirus," "Anemia," "Sickle cell anemia," "parvoviridae," "parvoviridae infection," and "parvovirus B19." Results Search results indicated 4 and 7 studies for the prevalence of the parvovirus B19 in beta-thalassemia and SCD, respectively. Among the beta-thalassemia patients, the B19V seroprevalence for IgG and IgM were ranged from 18.2-81% and 14.5-41.1%, respectively; meanwhile, B19V DNA positively results was 4-15.3%. Moreover, in the SCD group, the extent of B19V IgG was varied from 37.6 to 65.9% and that of IgM was in a range of 2.9-30%, and the DNA detection rate was 4-54%. Conclusion B19V seroprevalence changes in several conditions including, different epidemiological features, socio-economic status, and overpopulation. Age can expand the incidence of anti-B19V IgG/IgM in SCD and beta-thalassemia patients. Reinfection and diverse genotypes are relevant factors in the seroprevalence of B19v. The patients' immunological-hematological station and higher abundance of transfusions can affect the B19V seroprevalence in SCD and beta-thalassemia group. Further investigations in this field could be suggested to better understand the virus distribution in this susceptible population of patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up
    Ocak, Sabahattin
    Kaya, Hasan
    Cetin, Meryem
    Gali, Edip
    Ozturk, Muge
    ARCHIVES OF MEDICAL RESEARCH, 2006, 37 (07) : 895 - 898
  • [22] Myonecrosis in sickle cell anemia: Case report and review of the literature
    Vicari, P
    Achkar, R
    Oliveira, KRB
    Miszpupten, ML
    Fernandes, ARC
    Figueiredo, MS
    Bordin, JO
    SOUTHERN MEDICAL JOURNAL, 2004, 97 (09) : 894 - 896
  • [23] Prevalence and Genetic Analysis of α- and β-Thalassemia and Sickle Cell Anemia in Southwest Iran
    Forozan H. Nezhad
    Khojasteh H. Nezhad
    Parastoo M. Choghakabodi
    Bijan Keikhaei
    Journal of Epidemiology and Global Health, 2018, 8 : 189 - 195
  • [24] Prevalence and Genetic Analysis of α- and β-Thalassemia and Sickle Cell Anemia in Southwest Iran
    Nezhad, Forozan H.
    Nezhad, Khojasteh H.
    Choghakabodi, Parastoo M.
    Keikhaei, Bijan
    JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2018, 8 (3-4) : 189 - 195
  • [25] Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia
    Iannone, R
    Casella, JE
    Fuchs, EJ
    Chen, AR
    Jones, RJ
    Woolfrey, A
    Amylon, M
    Sullivan, KM
    Storb, RF
    Walters, MC
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (08) : 519 - 528
  • [26] On the road to gene therapy for β-thalassemia and sickle cell anemia
    Bank, Arthur
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2008, 25 (01) : 1 - 4
  • [27] Differentiation Between Sickle Cell Anemia and S/βο Thalassemia
    Fanestil, Vichaka
    Van Siclen, Carleen
    LABMEDICINE, 2015, 46 (03): : E79 - E81
  • [28] Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia
    Dong, Alisa C.
    Rivella, Stefano
    GENE AND CELL THERAPIES FOR BETA-GLOBINOPATHIES, 2017, 1013 : 155 - 176
  • [29] The Effect of L-Glutamine on Pain Crisis Reduction in Patients with Sickle Cell Anemia and Sickle β°-Thalassemia
    Anoosheh, Neda Farmani
    Keikhaei, Beijan
    IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2022, 12 (04) : 263 - 271
  • [30] Prevalence and incidence of erythrovirus B19 infection in children with sickle cell disease: The impact of viral infection in acute clinical events
    Brito Silva Furtado, Marina dos Santos
    Viana, Marcos Borato
    Hickson Rrios, Jessica Silqueira
    Lima Gontijo, Raquel Lais
    Silva, Celia Maria
    Rezende, Paulo do Val
    de Figueiredo, Rosangela Maria
    Martins, Marina Lobato
    JOURNAL OF MEDICAL VIROLOGY, 2016, 88 (04) : 588 - 595